Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
New Zealand retirement village operator Metlifecare has filed legal action aimed at forcing EQT Partners to fulfill an acquisition that it decided to terminate due to COVID-19.
Zentalis Pharmaceuticals, a US cancer treatment specialist that raised $165 million in an IPO last month, has secured $20 million in funding to establish a China-based joint venture.
US investors Optum Ventures and Health Catalyst Capital have co-led a $21.5 million Series A round for Singapore-based healthcare technology developer Holmusk.
The Hong Kong Stock Exchange has tightened disclosure requirements for companies looking to take advantage of two-year-old reforms permitting listings by pre-revenue biotech companies.
Japanese biotech developer Modulus Discovery has raised $25.5 million in Series B funding from a group of local VCs including SBI Investment.
Qitan Technology, a Chinese gene sequencing company, has raised RMB100 million ($14 million) in Series A funding led by Gaorong Capital. Other backers include Yinxinggu Capital and Yahui Preision Medical Fund.
Intel Capital has invested in two Chinese semiconductor suppliers and a Chinese medical technology developer as part of a $132 million commitment spread across 11 start-ups.
Hummingbird Bioscience, a Singapore and US-based drug developer with two cancer treatments on course to enter clinical trials, has received $25 million in an extended Series B round of funding led by the holding company of Korea’s SK Group.
The Carlyle Group has reached agreements that could see it pay INR16.3 billion ($216 million) for up to 74% of Indian animal healthcare services provider SeQuent Scientific.
Bain Capital has submitted a buyout offer for Nichii Gakkan, a Tokyo-listed provider of aged care, childcare and medical support services, that values the company at approximately JPY109.5 billion ($1 billion).
CVC Capital Partners plans to acquire 36.4% of HealthCare Global Enterprises (HCG) in a deal that ultimately could see it assume majority ownership of the Indian cancer care center operator.
Hamilton Lane has participated as a co-investor in a Japanese take-private for the first time, supporting a Polaris Capital Group-led tender offer for Sogo Medical Holdings, a Japanese pharmacy chain operator and B2B healthcare management platform.
Zenysis Technologies develops artificial intelligence-enabled systems that help governments improve healthcare management. CEO Jonathan Stambolis explains how demand has increased in response to COVID-19
Navis Capital Partners has taken a boutique private hospital to a new level of competence and professionalism just in time for the biggest healthcare emergency in living memory
Bugworks Research, a pharmaceutical company with operations in India, has raised $7.5 million in a funding round led by existing investors University of Tokyo Edge Capital (UTEC) and Global Brain.
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.
ChosenMed, a Beijing-based tumor detection company has raised a Series B round of more than RMB100 million ($14 million) led by state-owned Shanghai Lianhe Investment.
Beijing Mabworks Biotech has raised a RMB1.13 billion ($159 million) Series C round led by CICC Capital, Lyzz Capital, CITIC Securities Investment, and Huge Capital.
The Carlyle Group has sold 6.5 million shares of Metropolis Healthcare for INR7.5 billion ($98.7 million) to exit nearly its entire position in the Indian medical diagnostics chain.
Qiming Venture Partners has closed its seventh US dollar-denominated China fund at $1.1 billion following an approximately two-month process that involved a last-minute relocation of on-site due diligence from Shanghai to San Francisco.
Chinese drug developer Suzhou Ribo Life Science has raised RMB470 million ($66 million) in an extended Series C round led by China State-owned Capital Venture Capital Fund, CICC Capital and GL Ventures, the VC arm of Hillhouse Capital.
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.